Welcome to our dedicated page for Novavax SEC filings (Ticker: NVAX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Novavax, Inc. (NASDAQ: NVAX) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Novavax is a vaccine-focused biotechnology company that reports on its financial condition, material agreements, capital structure and key product and partnership developments through forms such as 10-K, 10-Q and 8-K.
Current Reports on Form 8-K for Novavax frequently address material events tied to its COVID-19 vaccine Nuvaxovid™/Nuvaxovid®, the Matrix-M® adjuvant platform and major collaborations. Examples include disclosures about the collaboration and license agreement with Sanofi, marketing authorization transfers for Nuvaxovid in the European Union and United States that trigger milestone payments, amendments expanding Sanofi’s license to use Matrix-M in pandemic influenza vaccine candidates, and milestone payments and royalties associated with partners such as Takeda. Other 8-K filings describe site consolidation transactions in Maryland, non-cash impairment charges, and convertible senior note exchanges and issuances that shape the company’s capital structure.
Periodic reports such as annual reports on Form 10-K and quarterly reports on Form 10-Q (when available) provide detail on Novavax’s revenue components, including product sales, supply sales and licensing, royalties and other revenue, as well as research and development and selling, general and administrative expenses. They also expand on risk factors related to regulatory approvals, manufacturing, partnerships and market adoption of its vaccines.
On Stock Titan, these filings are supplemented with AI-powered summaries that explain the significance of each document in clear language. Users can quickly see key points from lengthy 10-K and 10-Q reports, understand the impact of 8-K announcements on partnerships and financing, and review information about potential equity issuance and debt obligations, including convertible senior notes. The filings page also surfaces insider and executive-related filings, such as Forms 3, 4 and 5, when available, to help track equity ownership changes.
All documents are updated in near real time as they are posted to the SEC’s EDGAR system, allowing investors and researchers to review Novavax’s official disclosures, assess how collaboration agreements and regulatory decisions affect the business, and follow the evolution of its vaccine and adjuvant platform through formal reporting.
Novavax EVP, CFO and Treasurer James Patrick Kelly reported equity award activity involving restricted stock units (RSUs) and common stock. On March 7, 2026, 12,223 RSUs were exercised and converted into 12,223 shares of Novavax common stock at a stated price of
On the same date, 5,904 shares of common stock were withheld by the company at
Novavax Executive Vice President, CFO and Treasurer James Patrick Kelly reported an amended insider filing reflecting a grant of 194,000 non‑statutory stock options awarded on March 2, 2026. One-quarter of the options vest on the first anniversary of that date, with the remaining three-quarters vesting in equal monthly installments over the following three years, all conditioned on continued employment. The amendment only updates the exercise price previously reported; all other details remain the same, and the options are held directly.
NOVAVAX INC executive vice president of research and development Ruxandra Draghia-Akli reported an amended insider filing related to a previously disclosed stock option grant. On March 2, 2026, she was granted a non-statutory stock option covering 139,500 shares, held directly.
According to the filing, this Form 4/A was filed solely to amend the exercise price previously reported; all other information from the original March 5, 2026 Form 4 remains unchanged. One quarter of the option vests on the first anniversary of March 2, 2026, with the remaining three quarters vesting in equal monthly installments over the following three years, subject to continued employment.
Novavax Inc. executive Mark J. Casey reported an amended stock option grant. The Form 4/A updates only the exercise price originally reported for a non-statutory stock option covering 152,000 shares that was granted on March 2, 2026; all other details from the earlier filing remain the same.
The option was granted at no cash cost per option share and is held directly. One quarter of the 152,000 option shares vests on the first anniversary of March 2, 2026, and the remaining three quarters vest in equal monthly installments over the following three years, subject to continued employment.
NOVAVAX INC director and President and CEO John C. Jacobs reported a grant of 551,500 non-statutory stock options on March 2, 2026. This Form 4/A solely amends the exercise price originally reported in the prior Form 4; all other details are unchanged.
One quarter of the option vests on the first anniversary of March 2, 2026, with the remaining three quarters vesting in equal monthly installments over the following three years, subject to continued employment.
Novavax executive Elaine O’Hara, EVP and Chief Strategy Officer, filed an amended Form 4 to correct the exercise price previously reported for a 2026 non-statutory stock option grant covering 177,500 shares awarded on March 2, 2026. All other details from the earlier filing remain unchanged.
Under this option, one-quarter of the shares vest on the first anniversary of March 2, 2026, and the remaining three-quarters vest in equal monthly installments over the following three years, subject to her continued employment with the company.
Novavax EVP, CFO and Treasurer James Patrick Kelly reported equity award activity. On March 3, 2026, he acquired 43,167 shares of common stock through the exercise and vesting of restricted stock units at no cost. On the same date, 20,850 shares of common stock were withheld by the company at
Novavax Inc. President and CEO John C. Jacobs reported equity award activity. He exercised 150,167 Restricted Stock Units into an equal number of common shares at
Novavax executive Elaine O'Hara reported equity compensation activity involving restricted stock units and common shares. On March 3, 2026, she exercised or converted 56,334 restricted stock units, resulting in the acquisition of 56,334 shares of Novavax common stock at a stated price of $0.00 per share.
To cover tax withholding on this RSU vesting, 22,429 shares of common stock were withheld by the company at $9.49 per share, described as a tax-withholding disposition rather than an open-market sale. Following these transactions, O'Hara directly owned 134,642 shares of Novavax common stock. Footnotes state that one-third of the RSUs from this grant vest on each of the first three anniversaries of March 3, 2025, subject to continued employment.
Novavax EVP and Chief Legal Officer Mark J. Casey reported equity compensation activity involving restricted stock units and common stock. On March 3, 2026, 4,000 restricted stock units were converted and 37,500 shares of common stock were acquired through an exercise or conversion of derivative securities at a stated price of
In a related move, 11,378 shares of common stock were withheld at